Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2026, SmartHealth Catalyzer, Inc. is a biomedical venture studio located in the Midwest. The firm focuses on the commercialization of therapeutics, diagnostics, and medical devices developed at local universities and research hospitals. It has a portfolio of six companies and aims to address significant health challenges through life science innovations.
SmartHealth Catalyzer invests in life science innovations, specifically targeting therapeutics, diagnostics, and medical devices. The firm collaborates with universities and research hospitals in the Midwest to license groundbreaking biomedical innovations. Their support includes intellectual property protection, technology transfer, corporate creation, and operational strategy for early-stage life science companies.
Notable companies in SmartHealth Catalyzer's portfolio include Saros Therapeutics, which develops novel cancer medicines using the STING pathway; 32 Biosciences, focusing on gastrointestinal diseases; and bionode, which has a smartlens system for glaucoma patients. Other portfolio companies include Cadenza Bio, Delphian Therapeutics, and Atzeyo, each addressing critical health issues with innovative solutions.
Submit your pitch through their website's contact form for consideration.
SmartHealth Catalyzer typically participates in early-stage funding rounds, often leading investments in their targeted sectors.
The firm is open to follow-on investments, particularly for companies that demonstrate significant progress and alignment with their strategic focus.
Specific details about the fund size are not publicly available, but the firm actively invests in pre-seed to seed-stage companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.